Agenus shared a post on LinkedIn:
“ICYMI: At our October Stakeholder Webcast, Dr. Michael Gordon shared new pan-tumor data from more than 400 patients with refractory disease presented at ESMO2025 showing how BOT + BAL are challenging long-held limits in immuno-oncology.
Watch the full discussion and data highlights on demand.”
More posts featuring Agenus on OncoDaily.